Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4137914-A4137914, November 12, 2024. This included an HbA1c>7.0%, age>50 with established CVD, heart failure, or chronic kidney disease or an age>60 with at least one CVD risk factor. year follow-up time).Results:Among Results:Among 5002 (projected to 34.0

Diabetes 40

Diabetes Blood Pressure Myocardial Infarction Kidney Disease 40

DAIC

APRIL 7, 2024

mtaschetta-millane Sun, 04/07/2024 - 18:43 April 7. mtaschetta-millane Sun, 04/07/2024 - 18:43 April 7. High blood pressure, or hypertension , is a leading cause of heart attacks, strokes and death. It occurs when the heart has to work harder to push blood through the blood vessels, increasing pressure inside the vessels.

Blood Pressure 111

Blood Pressure Heart Attack Heart attacks Hypertension 111

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. Orchestra BioMed and Medtronic, Inc. and Europe.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

Dr. Paddy Barrett

NOVEMBER 1, 2024

Death from heart disease: 51% reduction in risk. High Blood Pressure: 37% reduction in risk. Kidney Disease: 42% reduction in risk. British Journal of Sports Medicine 2024; 58: 556-566. Death from any cause: 53% reduction in risk. Cancer deaths: 43% reduction in risk. Heart Failure: 69% reduction in risk.

Exercise 119

Exercise Heart Disease Quality of Life Blood Pressure 119

Cardiometabolic Health Congress

JULY 17, 2024

The first half of 2024 has ushered in a wave of transformative FDA approvals in cardiorenal metabolic health. Edwards EVOQUE Tricuspid Valve Replacement System (Approved: 02/01/2024) This system provides a novel approach to tricuspid valve replacement, potentially benefiting patients with tricuspid regurgitation without open-heart surgery.

Tricuspid 59

Tricuspid Open-Heart Surgery Kidney Disease Pediatrics 59

DAIC

JUNE 28, 2024

milla1cf Fri, 06/28/2024 - 19:07 June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa , its flagship health equity initiative, to target a broader range of non-communicable diseases (NCDs), including chronic kidney disease (CKD) as well as hypertension and cardiovascular disease.

Kidney Disease 111

Kidney Disease Blood Pressure Cardiovascular Disease Hypertension 111

CardiacWire

OCTOBER 6, 2024

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), blocking the mineralocorticoid receptor and its blood pressure effects. Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

DAIC

MAY 16, 2024

A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).

Peripheral Arterial Disease 105

Peripheral Arterial Disease Exercise Ischemia Quality of Life 105

Cardiometabolic Health Congress

JULY 10, 2024

Bakris , an internationally recognized and influential nephrologist and hypertension expert, who passed away on June 15, 2024, at the age of 72. Bakris’s distinguished career in medicine spanned over four decades, marked by significant contributions to the fields of diabetic kidney disease, hypertension, and nephropathy progression.

Hypertension 52

Hypertension Education Blood Pressure Kidney Disease 52

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024. Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure.

Myocardial Infarction 40

Myocardial Infarction Blood Pressure Heart Failure Kidney Disease 40

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4145840-A4145840, November 12, 2024. Introduction:High levels of blood pressure (BP) are responsible for 7.6 The diagnosis of hypertension is associated with a significant increase in the risk of kidney or cardiovascular events, with no prior history of these events.

Hypertension 40

Hypertension Heart Failure Certification Kidney Disease 40

DAIC

JANUARY 23, 2024

11 Despite the link between inflammation and cardiovascular disease has been proven by extensive research, most physicians have focused on treating high-risk patients with lipid lowering therapies including statin therapy.1,12,13 Anti- inflammatory Therapy for Cardiovascular Disease. Elsevier; 2024:224-235. μ/L on 0.6

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. Disparities in care are also concerning, with diagnosed cardiometabolic diseases varying up to twofold among different racial and ethnic groups. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103